Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 491 of 5804
-
Could a Lower-Dose RSV vaccine protect babies just as well?
⭐️ VACCINE ⭐️ TerminatedThis study is a Phase III, parallel group, randomized, observer blind, placebo controlled, multi-national, multi-center, multi-arm study to be conducted in 947 healthy children enrolled at 6 months to \<22 months of age. The purpose of the study is to evaluate the non-inferiority…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
New mRNA HIV vaccine trial aims to train immune system to fight virus
⭐️ VACCINE ⭐️ OngoingThis is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred t…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
One-of-a-Kind ALS drug shows promise in first human test
Disease control CompletedThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy drug nivolumab takes on rare childhood cancer
Disease control Recruiting nowInvestigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to tame stubborn high blood pressure
Disease control CompletedThe main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).
Phase: PHASE3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat KRAS cancers
Disease control Recruiting nowThis is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The s…
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Frozen testicle tissue may help men become dads after childhood cancer
Disease control Recruiting nowFreezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells in case of imminent gonadotoxic treatment during childhood. In case of total azoospermia or absence of spermatozoa that can be used for intra-cytoplasmic injection (ICSI) in adulth…
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New targeted therapy aims to extend life in stomach cancer
Disease control Recruiting nowThe study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
Phase: PHASE3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Major trial tests if zapping heart tissue beats pills for common rhythm disorder
Disease control Recruiting nowAtrial fibrillation (AF) is a common heart rhythm disorder that causes an irregular heart beat and is a cause of heart failure (HF). Treatments include drugs to slow the heart rate, anti-arrhythmic drugs or ablation of the heart to help preserve normal rhythm. A number of trials …
Phase: NA • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could diabetes drugs protect kidneys after acute injury?
Disease control Recruiting nowAcute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD). Despite knowing this, there is no proven treatment to improve outcomes f…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThe purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control OngoingThis study is a multicenter, randomized, uncontrolled clinical trial to evaluate the efficacy and safety of camrelizumab combined with or without apatinib and SOX of neoadjuvant treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New trial tests best timing for sepsis drug to save lives and kidneys
Disease control Recruiting nowThe norepinephrine and vasopressin for rescue versus early vasopressin for vasopressor dependent sepsis (NoVa) is a phase 3, multicenter, open-label, randomized controlled trial comparing an early vasopressin initiation strategy versus norepinephrine plus vasopressin initiation o…
Phase: PHASE3 • Sponsor: Hospital do Coracao • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug vimseltinib aims to tame chronic GVHD in failed treatments
Disease control Recruiting nowThe purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Phase: PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Supercharged immune cells take on hard-to-treat cancers
Disease control Recruiting nowPhase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors. The safety and effects of KSQ-004EX will also be studied …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New asthma drug aims to slash severe attacks in eosinophilic patients
Disease control Recruiting nowThe purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Trikafta's long-term safety tested in toddlers with cystic fibrosis
Disease control OngoingThe purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Single shot could replace monthly eye injections for wet AMD
Disease control OngoingThis is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Participants will be enrolled in one of 2 parts: * In Part I (dose escalati…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New weekly shot shows promise for weight loss and diabetes
Disease control OngoingThis is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for lymphoma patients: antibody drug targets residual cancer after chemo
Disease control Recruiting nowThis research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC